v3.26.3
Acquisition of Ascyrus (Details)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Sep. 02, 2020
USD ($)
Jul. 31, 2026
USD ($)
Jun. 30, 2026
Sep. 30, 2026
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2026
USD ($)
Sep. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Business Combination [Line Items]                
PMA approval payment           $ 11,686 $ 0  
Change in fair value of contingent consideration           13,738 2,390  
Ascyrus Medical LLC                
Business Combination [Line Items]                
Equity ownership percent 100.00%              
Cash consideration $ 60,000              
Common stock value issued in business combination 20,000              
Payment for contingent consideration   $ 25,000            
Payment for contingent consideration liability, operating activities   13,300            
PMA approval payment   $ 11,700            
Maximum amount of future consideration payment       $ 75,000   75,000    
Change in fair value of contingent consideration       1,100 $ 2,600 10,800 $ 2,400  
Contingent consideration, probability of achieving milestone, percentage     100.00%          
Business combination, contingent consideration, liability       $ 46,400   $ 46,400   $ 60,600
Ascyrus Medical LLC | Measurement Input, Discount Rate                
Business Combination [Line Items]                
Contingent consideration, measurement input       0.17   0.17    
Ascyrus Medical LLC | FDA Approval IDE for AMDS                
Business Combination [Line Items]                
Cash consideration 10,000              
Common stock value issued in business combination 10,000              
Ascyrus Medical LLC | FDA Approval PMA for AMDS                
Business Combination [Line Items]                
Cash consideration 25,000              
Ascyrus Medical LLC | AMDS Obtained In Japan                
Business Combination [Line Items]                
Cash consideration 10,000              
Ascyrus Medical LLC | AMDS Obtained In China                
Business Combination [Line Items]                
Cash consideration 10,000              
Ascyrus Medical LLC | Additional Potential Cash Payment If Japan Or China Obtains Approval                
Business Combination [Line Items]                
Cash consideration $ 55,000              
Ascyrus Medical LLC | Following FDA Approval For AMDS                
Business Combination [Line Items]                
Period of required contingent consideration 3 years              
Ascyrus Medical LLC | Maximum                
Business Combination [Line Items]                
Aggregate amount of consideration transferred $ 200,000              
Ascyrus Medical LLC | Maximum | Additional Potential Cash Payment If Japan Or China Obtains Approval                
Business Combination [Line Items]                
Cash consideration 75,000              
Ascyrus Medical LLC | Minimum | Additional Potential Cash Payment If Japan Or China Obtains Approval                
Business Combination [Line Items]                
Cash consideration $ 65,000